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EDITORIAL
Provision of services to patients with chronic uremia
Victorian partygoers amused themselves by playing the
balloon game. The participants imagined they were de-
scending to earth in a balloon from which one must be
jettisoned if the others were to survive. Each explained
why he was too valuable to the community to be thrown
out. The audience judged. It was good clean fun because it
could never happen in real life —but it did. In 1960 the
scene was re-enacted with public spirited citizens as jury
and patients with renal failure as contenders, and this time
it was in earnest; all those who failed to find a place on the
first community dialysis program were dead within a
year [1]. This spectacle of selection by social worth was so
repugnant that it was soon hidden from the public view.
Lay committees were abandoned and physicians became
almost the sole arbiters [21 but considerations of social
suitability, including personal attractiveness, continued to
play a considerable part in selection [2]. In spite of a large
infusion of federal funds through the Public Health
Service [3] and Veterans Administration [4, 5], a survey in
January 1968 [2] showed that ability to pay still played an
important role; the dialysis population was biased in favor
of high income, compared with the U.S. average. Moreover
about 30% of the patients had drawn on savings, 20% on
relatives, 20 % on veterans benefits and 25 % on company
insurance, a fact that suggests that access to these alter-
native sources of finance was equally important in selection.
In 1967 the Gottschalk Committee [4] made a conser-
vative estimate that while 20% of the patients dying of chro-
nic renal failure in the United States would be suitable for
treatment by dialysis or transplantation, only one in seven
would obtain it in 1968. The situation was said to be "no
longer tolerable" and the Committee stated that federal
assistance was mandatory to defray the high cost of treat-
ment. "We recommend that a national program be initiated
for the treatment of endstage renal failure . . . for all of the
American population for whom it is medically indicated";
and "we see no justification for selection of candidates for
dialysis or transplantation on the basis of ability to pay."
The Committee drew up a national program that would
ensure that 72% of the suitable patients would be treated in
1972 and 100% in 1973. The Burton Committee [6] also
submitted a report in 1967 to the Surgeon General on
preventive nephrology and the treatment of renal failure.
The report proposed rapid expansion of Department of
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Health, Education and Welfare expenditures on dialysis,
transplantation and associated research to provide com-
prehensive treatment on an annual budget rising to $162
million in 1975. This figure was based on the optimistic
assumption that the increased research expenditure would
surely produce the answers by 1975. In that year the research
budget could drop to $1 million for the entire country (!)
and correspondingly the cost of dialysis would fall to
$3,000 per patient per year.
The response of the US government to these reports has
not, to my knowledge, been published. However, until the
recent provision of medical coverage to those eligible for
Social Security benefits (to be effective in July, 1973) it
was readily apparent to the visitor from abroad that a
national program on this scale had not yet been launched
and that much of the recent expansion in dialysis and trans-
plant facilities had taken place through the normal state
and private medical systems, boosted by an upsurge of
franchise centers.
Most European countries by the mid-1960's were
operating some form of socialized medicine and were
committed, in theory at least, to the provision of total
health care by the state. Nonetheless few governments were
ready to accept the challenge posed by the new treatments
for renal failure and even their medical advisers did not
contemplate expenditure on the scale suggested by the
Gottschalk and Burton Committees. Sweden was alone in
making an early decision to offer treatment to all medically
suitable patients and to plan national provision on that
basis [7], but other Scandinavian countries are now follow-
ing her lead. In France, in spite of a pre-eminent position in
transplantation, a program of regular dialysis grew slowly.
A colloquium in 1966 [8] estimated that 1,000 to 1,250 new
patients annually, from the population of about 50 million,
would be suitable for dialysis. Targets were set in a program
of gradual build-up of national facilities including the
opening of 55 dialysis centers and the treatment of 1,850
patients by the end of 1971. A survey conducted before the
second colloquium in 1970 [9] showed that only half the
target figures had been achieved and that there were wide
local differences in provision of dialysis places— from 20
per million in Alsace to none at all in five other regions.
The conference renewed the call for a national plan and for
the formation of a Bureau National de Coordination de la
Dialyse Périodique, but there was no mention of treatment
for all who needed it.
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Great Britain made an earlier but still cautious start.
Between 1963 and 1965 regular dialysis and transplantation
were limited to a few centers where local enthusiasm had
wrung a pittance from National Health Service (NHS)
sources and voluntary funds. In 1965 a conference at the
Ministry of Health declared that regular hemodialysis was
now an established form of treatment which should be
provided under the NHS, but opinion was sharply divided
on how much priority this new service should be given [10].
In a characteristic British compromise, some priority was
assured by the diversion of funds centrally but initial ob-
jectives were limited to the creation of one dialysis center in
each of the NHS administrative areas, which serve a pop-
ulation of about 2—3 million [11, 12]. A major function of
these units was the training of staff for a second generation
of hospital centers, which have not materialized. In 1967
home dialysis was officially encouraged, and at the same
time transplant facilities have gradually expanded with
direct government support. The planning and execution of
the British program is well documented in reports circulated
by the Departments of Health from data collected annually
from all NHS centers. The details of these reports, in-
cluding the aspirations and achievements of individual
units, are confidential, but the over-all figures may be
published and are summarized in Table 1 and Figs. 1 and 2.
It is clear from Table 1 that no major expansion of
hospital dialysis facilities is planned. There is generous
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Fig. 2. Preferential expansion of home dialysis in England and
Wales. Data supplied by Department of Health and Social
Security.
1 funding for the growth of home dialysis (Fig. 2), but this
branch of treatment is retarded by its inherent difficulties
522 and by the reluctance of local authorities to participate
76% rapidly in rehousing or home adaptation [13, 14]. The main
888 brake on expansion of the transplantation program is the
shortage of cadaver kidneys. The supply is improving and
772 the National Organ Matching Service is now handling
2400 kidneys at a rate equivalent to 500 per annum [15, 16].
However, if the supply continues to improve, a new bottle-
neck will soon appear in the availability of in-patient beds
for transplantation patients —a shortage that can be correct-
1044 ed only over a long time span since these centers must be
564 located in large teaching hospitals where building is difficult
80 and expensive. It is therefore inherent in British plans— and
openly admitted by the medical press [17, l8]—that com-
(9°/) prehensive treatment will not be achieved in the foreseeable
265 future and that "selection for this form of treatment will
remain a doctor's dilemma for many years to come" [18].
An all-important factor in the recent trends in British
practice has been the spread of hepatitis [19]. The unusually
severe mortality rate among staff and patients in two
British outbreaks led to a strong prejudice against per-
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Table 1. Facilities for regular dialysis in England and Wales as
of June 30, 1972a
24
18
Active Dialysis Centers
Major'
Smallere
Planned Dialysis Centers
Hospital Patients
Current
% in recipient pool
Eventual capacity
Home Patients
Current
% in recipient pool
Eventual capacity (approx)
New Intake, July 71 to June 72
per million population/year
Calculation of Mortality Risk
On dialysis, Jan. 7, 1971
Started 1971—1972
Failed transplant, 197 1—1972
"At risk", 1971—1972
Died
Transplanted
a Population approx. 50 million. Based on data collected by the
Department of Health and Social Security.
b Maximum capacity 20 or more patients.
c Maximum capacity less than 20 patients. Mainly home training
centers, transplant support facilities and satellites.
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rnanent hospital dialysis. A recent survey (unpublished) of
British dialysis centers shows that nearly all have cleared
their hospital units of hepatitis carriers by transfer to home
dialysis, transplantation or spontaneous reversion of pa-
tients from carrier state to normal. This, combined with
early identification and isolation of cases, appears to have
halted the spread of hepatitis in Britain [20], in contrast to
Europe as a whole where the problem is still rampant [211.
In Australasia, a very different approach from that
developed in Great Britain was adopted. Early emphasis
was on renal transplantation, and dialysis facilities were only
developed as far as was necessary to support the transplant
program; home dialysis was virtually unexplored [22, 23].
Combined with a very active kidney retrieval, this system
met the needs of the communities in this region to a much
greater extent than did the emphasis on dialysis in Britain;
175 out of 190 patients presenting with renal failure at
Sydney in a two year period were accepted [23]. Little
attention was paid to close tissue matching. Patients who
lost a kidney were usually re-transplanted or died; there
were few permanent returns to the dialysis program [24].
In spite of these differences in initial plans, methods and
vicissitudes, nearly all countries in North America, Europe
and Australasia are now moving toward a common goal —
the establishment of integrated dialysis and transplantation
services [25—28]. These systems have a strong emotional
appeal. They offer the patient security and hope, the hope
of release from the restrictions of dialysis by a transplant
and the security of knowing that he will be welcomed back
onto dialysis if his transplant fails. These feelings are im-
portant even when they are illusory. Such integrated centers
also preserve doctors from the uncertain career prospects
that go with narrow specialization in one treatment area
and allow a broader training of junior staff. Integrated
treatment centers are therefore likely to become the normal
pattern whatever the survival statistics may show about
the superiority of one treatment over another. However,
because of our different approaches, we have progressed at
different speeds toward the goal of treatment for all and it
is instructive to pause and review how far we have come.
How great is the need? How wide is the gap? How can we
close it faster?
How Great is the Need?
The first estimate of the need for dialysis or/and trans-
plantation was conducted by questionnaire to physicians
around Seattle and suggested a potential of 5 to 20 patients!
million/year [29]. A parallel study from life insurance data
gave a figure of 10/million/year for patients selected by the
strict criteria then in force. However it was readily admitted
that many excluded by these criteria would have made good
dialysis candidates [1]. In Sweden [7, 30] and in San Fran-
cisco [31] estimates were based on retrospective analysis of
hospital case notes, autopsy data etc., derived from a discrete
geographical area; the samples were necessarily small. Most
of the other estimates which guided (or deterred) our
planners in the 1960's [4, 6, 32—34] were based on death
certification statistics, a notoriously unreliable source and
particularly suspect in the case of renal disease; several
surveys [35—37] have shown that fashions in certification
play a larger part in these figures than true disease incidence.
Nonetheless the errors in retrospective analysis seem to
cancel one another out and the answers obtained were
quite close to those provided later by more accurate
methods [38]. Recently prospective studies have been per-
formed in three areas of Great Britain [39—41]. In a few
dialysis centers with relatively open policies, admission
rates reflect the total number of suitable candidates very
closely [23, 26].
It is obvious from these surveys that the most important
variables are the criteria of suitability for treatment. A
decision whether the upper age limit should be 55 or 65
affects the answer much more than the errors of retrospec-
tive analysis or the difference between mortality rates in
different developed countries. The suggested figures have
varied from about 25 to 75 patients/million/year depending
on which upper age limit is accepted. Perhaps the best
verified estimates are those derived from the prospective
studies in Scotland [41] and Northern Ireland [40], which
gave figures of 38 and 33/million/year for patients up to
age 55 and (in Scotland) 52/million/year for patients up
to 65. However these figures are heavily influenced by
decisions about suitability. The main reason for exclusion
was the presence of cardiovascular disease, which is cer-
tainly not universally regarded as a cause for rejection
from dialysis and transplant programs. If this and other
controversial reasons for exclusion were dropped and the
upper age limit was fixed at about age 65, the suitable
candidates could be as numerous as the 70 to 80/million/
year found in Israel [38] and one American center [26].
So far patients over age 55 have comprised less than 10%
of the hospital dialysis population [21] and an even smaller
proportion of those treated by home dialysis or transplan-
tation [21,42,43], although about half the deaths from renal
failure occur in this age group. Only when we have adequate
facilities to treat all of those requesting treatment will we
know how many of these older patients are really suitable
for dialysis. Even then the answer will never be clear-cut
for suitability is relative.
The new intake of patients with chronic renal failure is
only one factor determining the need for dialysis and trans-
plant facilities. Others include the survival rates on each
form of treatment, the supply of cadaver kidneys and the
proportion of patients with failed transplants who are
successfully returned to dialysis. The effect of these variables
has been discussed by Farrow, Fisher and Johnson [44]
who have constructed a mathematical model to predict the
dialysis and transplant population in an integrated service
and the rate at which dialysis places, transplant cubicles,
etc., become necessary. They have shown that an equili-
brium state is achieved after about 12 years of constant
conditions. Since it is extremely unlikely that survival rates
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Fig. 3. Number of dialysis renters reporting to the EDTA [21].
Reproduced by permission of the authors and the Editor of the
EDTA Proceedings, as are Figs. 4—7.
will remain steady for that period, long term predictions of
this type will not have much practical application. However
a model of this type should be helpful in planning two or
three years ahead, provided the information is updated
regularly. This updating requires the regular publication
of national or international survival data, a task which is
performed in Europe by the European Dialysis and Trans-
plant Association. For the last two years the Association
has combined its surveys of dialysis and transplantation
into one report [21, 46], in recognition of the fact that these
forms of treatment are complementary. The data collection
has been greatly simplified, duplication with other surveys
has been eliminated and key men have been appointed in
each European country to keep the registry informed about
new centers and to encourage complete reporting. As a
result, the registry received complete reports from over 95 %
of the known centers in Europe in 1971 [21] and the rise in
number of participating centers (Fig. 3) reflects better re-
porting as well as increasing activity.
The survival rates shown in Fig. 4 were calculated by the
actuarial method on 10,819 hospital and 1,424 home dia-
lysis patients, 568 living donor and 2,479 cadaver donor
transplants. Some caution must be exercised in interpreting
such multinational data; two thirds of the European home
dialysis patients are in Britain so comparison of this group
with hospital dialysis and transplant is biased. However an
independent British survey [46] has confirmed that home
dialysis gives the highest survival rate, an observation which
is no doubt partly explained by selection. Both the EDTA
and Human Renal Transplant Registry [42, 43] figures show
that the survival of cadaver grafts is now changing little
from year to year. The results of hospital dialysis are also
changing little at the moment [21] and are similar to those
reported four years earlier by Lewis et al in the USA [3].
There are no recent actuarial data for the USA but the
National Registry of Long Term Dialysis Patients [47]
reports an annual mortality of about 9% of all patients at
risk, a figure which is close to the one calculated similarly
on British data in Table 1. It is therefore likely that results
are much the same on the two sides of the Atlantic. Some
of the information needed to operate Farrow's model is
still lacking. Does the home dialysis patient who loses a
transplant usually return to home dialysis or does he remain
in the hospital unit? Is his survival the same as that of
patients who have never been subjected to surgery and
immunosuppression? Is the correlation between transfusion
history and graft survival (Fig. 5) entirely due to an adverse
effect of transfusion, which can be avoided, or is it partly a
reflection of time on dialysis? Until these and similar ques-
tions can be answered it is hardly worthwhile using a
sophisticated method to guess the equilibrium population.
However it is of some interest to know what sort of burden
we would carry if present techniques were exploited to their
fullest with present success rates. I have made a simplified
calculation in Table 2.
The figures in Table 2 are based on a number of simpli-
fying assumptions. 1) All patients are placed on regular
hemodialysis before transplantation; this is true of 97%
of European transplants [21]. 2) All suitable patients on
461
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Patient survival LD
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Graft survival LD
Patient survival CAD
Fig. 4. Survival rates following various forms of treatment in
Europe 1969—71 [21]. LD=living donor graft; CAD=cadaveric
graft.
Fig. 5. Cumulative rate of graft failure by rejection in relation to
blood transfusion experience, Europe 19 70—71 [21].
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Treatment
Admission rate
25/million/year
Admission rate
50/million/year
Annual Equilibrium Annual Equilibrium
cohort population cohort population
Live donor graft 2.5 18 5 35
Home dialysis 18 32 22.5 40
Hospital dialysis 4.5 8 22.5 37
Cadaver graft 20 97
155/
millionb
39 189
301/
millionb
a Survival rates taken from EDTA report [211, linear survival
curves drawn by eye from second year on.
b This calculation is based on many simplifying assumptions,
some of which are listed in the text. It is intended only as a
rough guide for comparison with actual achievement (Table 3).
dialysis will be offered a transplant. Even in Britain, where
home dialysis has received the greatest emphasis, two-
thirds of the home patients and three-quarters of the hospital
patients are regarded as suitable for transplantation
(Table 1). This is a new shift in emphasis so I have assumed
that 80% of all dialysis patients will eventually be offered
a graft, including those in the older age group who now
feature in European transplant data [211. 3) Only one
cadaver graft will be offered to each patient in view of the
very poor results of second and subsequent grafts (Fig. 6).
4) The subsequent survival of patients with failed cadaver
grafts will follow the "Patient survival CAD" graph in
Fig. 4, whether they return to hospital or home dialysis.
5) The supply of cadaver grafts will be adequate, since the
Australians have shown that this is possible. 6) The average
waiting time for a cadaver graft will be two years; the true
figure will depend on the emphasis given to accurate tissue
typing. In view of the equivocal evidence for its value in
cadaver grafting (Fig. 7)1 have assumed that it will be used
but will not be an overriding consideration. 7) Live donor
grafts will be available for only 10% of transplanted pa-
tients as in Europe in 1971—1972 [21, 46]. The much higher
figure (47%) quoted in the Tenth Report of the Human
Renal Transplant Registry [43] for the USA reflects past
emphasis on live donor grafting and could certainly not be
maintained in the face of an expanded intake. 8) Three-
quarters of all dialysis patients would be in the home if
intake remained restricted; this is the direction in which
Britain (Table 1) and the USA [47] are currently heading.
9) If intake were expanded only half the patients could be
sent home, in view of the small proportion of European
patients over age 55 so far transfered to home dialysis [21].
10) The average time necessary to train and establish a home
dialysis patient is six months. The true figure for Britain is
between four and five months [21] but it might well increase
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Fig. 6. Cumulative survival after cadaver kidney grafting in
Europe, 1969—71 [21].
2 Identities
..—::
 3 Identities
._———"—"—..— 4 Identities
Fig. 7. Cumulative rate of graft failure by rejection in relation to
tissue matching grade, first cadaver grafts [21].
need separate consideration. They are an important group
who are now treated successfully by dialysis or transplan-
tation [48—54], and they will probably be handled differently
from adults with freer use of live donors [21]. However they
constitute so small a proportion of the total potential intake
that they will not appreciably distort the figures.
How Wide is the Gap?
The two rates of intake of patients shown in Table 2 are
taken from the middle and the bottom of the range of
estimates for potential candidates, but has any nation
reached even the bottom figure? There is no published
"league table" from which to answer this and it is to be
hoped that the EDTA, which has the information, will
include it in the next annual report. England and Wales
(Table 1) have an intake of 13/million/year. This goes a long
way toward meeting the needs in the age group 15 to 45
but leaves the extremes of age largely untouched [46]. The
over-all intake for the 460 million Europeans covered by
the EDTA report [21] was somewhere between 9 and
11/million in 1971 (the data quoted do not permit an exact
calculation). A rough figure for the USA can be calculated
from the Renal Transplant Registry reports [42, 43] and
the National Registry of Long-Term Dialysis Patients [47].
During the first four months of 1971 the dialysis population
increased at the rate of about 1,800/annum. Since the mor-
tality rate was about 9%, the intake to dialysis units must
Table 2. Approximate equilibrium population of dialysis and
transplant patients expected from current survival ratesa at two
100different rates of admission 90
80
70
60
50
40
30
20
10
123 6 i 7 Years
40
30
20
10
if the intake of patients were expanded. 11) Children do not have been around 2,000/annum plus whatever number were
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Table 3. Dialysis and transplant survivors per million population
on December 31, 1971a
Countryb Population
(millions)
Patients per million Proportion
of dialysis
patients inOn With Total
dialysis graft the home
(%)
Denmark 4.9 29 41 70 2
Switzerland 6.3 43 18 61 7
Sweden 8.0 28 26 54 18
Netherlands 13.0 37 9 46 7
Belgium 9.6 27 15 44 1
France 50.8 31 6 37 8
Finland 4.7 16 15 31 2
Britain 55.7 21 9 30 56
USA 18 ?12—1830—35 39
Australasia 16 30—40 low
a European data from EDTA report [21].
b All European countries not listed have less than 30 survivors
per million. European mean is 21.7 per million.
transplanted and did not return to dialysis. The latter
number is not known but a total of 1,556 USA transplants
were reported to the Human Renal Transplant Registry in
eight and one-half months of 1971 [42, 43], a rate of about
2,200/year. The Registry reports give no data on how
completely they cover the USA but if one assumes that a
little under-reporting cancels out a little double-counting,
a rough figure of 15 to 18/million/year emerges. There is
plenty of information on Australasian transplants but little
on their dialysis program. During 1969 and 1970 the
transplant rate leveled out at about 13/million/year [55].
There is a recipient poo1 of 260 patients who have accu-
mulated in the last few years [56] 50 the total intake must
have been appreciably above 13, probably in the range of
15 to 20/million/year.
The total population being kept alive by dialysis or/and
transplant is shown for some representative European
countries in Table 3. A fuller list is given in the EDTA
report [21]. No exact figure can be calculated for the USA
but in April, 1971, the dialysis population was about 18/
million [47]. The proportion of American transplants,
totaling about 23/million to the end of 1971 [47], which
were still functioning at that time is unknown; however
since nearly a third were performed in 1971 and almost half
were from live donors, it is probably over half. The com-
posite American dialysis/transplant population must
therefore be of the order of 30—35/million. In Australasia,
with a population of 16 million, there were 260 patients in
the recipient pool (presumably on dialysis) in July, 1972
[56], 211 transplant survivors at the end of 1970 and about
200 new transplants a year with a one year graft survival
of about 55% [55]. From these data one can make a
guess of about 30—40 dialysis and transplant patients/
million at the end of 1971.
it is clear that every country has a long way to go before
reaching the equilibrium population expected even from
present techniques. After five years of steady intake the
dialysis/transplant population should be about 80% of its
equilibrium level [47], but no country is even approaching
this point.
Can We Close the Gap Faster?
Certainly we can if we are granted more money, staff and
resources. As advocates for our patients we should press
our goverments to provide these. Meanwhile, can we do
better with our present resources? Table 3 suggests that a
high performance, by present standards, can be achieved
by concentrating on hospital dialysis (as in Switzerland,
Netherlands and France) or on transplantation (as in
Scandinavia and Australasia) with transplant probably the
better short-term bet. But will the advantage be maintained?
The question is of particular interest to Britain and has
been explored by Farrow, Fisher and Johnson [57] using
their mathematical model, In view of the figures in Table 1,
they have had to assume that our hospital dialysis facilities
will not expand but by utilizing them to the full England
and Wales could achieve an annual intake of 22.5/million,
assuming a two-year wait for a cadaver kidney. A switch
in emphasis to transplant, which cut the waiting time for a
graft to one year, would increase the annual intake by about
20% but after five years the population of survivors would
be only 10% greater and those with functioning grafts only
7 % more numerous. They concluded that an all-out effort
at kidney retrieval was scarcely worthwhile as long as
cadaver graft survival remained at the present level. It
needs no mathematical legerdemain to show that the greatest
advantages would accrue from better survival of cadaver
grafts and more intensive utilization of hospital dialysis
facilities.
Although international performance with cadaver graft-
ing is almost at a standstill [21, 43], many individual centers
report results which are much more encouraging. Are these
due to chance in small numbers or to superior techniques?
If the latter, what are these techniques? We remain woe-
fully ignorant, for very few procedures used in transplan-
tation have been subjected to controlled trial. Splenectomy,
thoracic duct drainage, graft irradiation, Actinomycin,
heparin, warfarin, dipyridamole, aspirin, steroid "pulse"
therapy and a long list of other devices have been added to
the standard regime in innumerable uncontrolled experi-
ments and their value remains entirely speculative, though
their hazards are beyond dispute. Now that we are pooling
our data for statistical purposes can we not go one step
further and combine to subject this branch of therapeutics
to the discipline of the controlled trial?
The intensive use of hospital facilities is limited by short-
age of nurses and fear of hepatitis. in some countries it is
also inhibited by the use of long dialysis time. This was
once necessary to insure against poor blood flow through
the dialyser and to permit adequate removal of water,
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sodium, potassium, phosphate and urate. The A—V fistula,
modern dialysers, phosphate binders and allopurinol can
overcome these problems but they are being replaced by a
fear that unidentified "middle molecules" will accumulate
if dialysis time is reduced. It is therefore interesting to see
that the latest EDTA report [211 shows no correlation be-
tween survival or rehabilitation and membrane thickness
in the dialyser, an unexpected result if "middle molecules"
are of critical importance in uremia. Further work on the
middle molecular hypothesis [58] will be watched with
great interst, but it should not at this stage inhibit experi-
ment into shorter dialysis time. It should be emphasised
however that any reduction should not be achieved by
decreasing the frequency of dialysis since the value of thrice
weekly dialysis is as well established as any fact in the ma-
nagement of terminal renal failure [21].
D. N. S. Kerr
Newcastle upon Tyne,
England
Reprint requests to Prof. D. N. S. Kerr, Royal Victoria Infir-
mary, Newcastle upon Tyne NEJ 4LP, England.
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